SHOULDER INNOVATIONS, INC. SI

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NYSE

We are a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. We currently offer advanced implant systems for shoulder arthroplasty. These systems are a core element of our ecosystem, which we designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Our ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care. We believe our exclusive focus on shoulder surgical care, combined with a highly specialized commercial organization and strong clinical data, positions us well to capture significant share in this large, growing market.

Last close 20.32 2026-09-04
Market cap $423.0M 2026-06-30 share count
52-week range 10.92 - 24.59

Valuation FY2025 figures against the last close

P/S8.9x
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS-4.65

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023
Revenue $47.3M$31.6M
Cost of revenue $11.1M$7.3M
Gross profit $36.2M$24.3M
R&D $7.7M$4.5M
SG&A $54.8M$34.5M
Operating income -$26.3M-$14.7M
Interest expense $70.0K$1.3M
Pre-tax income -$40.4M-$15.6M
Income tax $0$0
Net income -$40.4M-$15.6M
EPS, basic -4.65-242.04
EPS, diluted -4.65-242.04
Shares, diluted (wtd. avg.) $8.7M$64.5K

Balance sheet

Fiscal year FY2025FY2024FY2023
Cash and equivalents $26.9M$6.1M$6.2M
Short-term investments $97.4M$8.9M
Receivables $8.3M$5.1M
Inventory $21.6M$14.0M
Total current assets $157.2M$35.1M
Property, plant and equipment $12.5M$7.5M
Other intangibles $100.0K$400.0K
Total assets $169.9M$43.1M
Accounts payable $8.9M$4.9M
Total current liabilities $14.2M$7.6M
Long-term debt $14.9M$14.7M
Total liabilities $29.2M$23.3M
Retained earnings -$97.4M-$57.0M
Total equity $140.8M-$54.7M-$39.7M

Cash flow

Fiscal year FY2025FY2024FY2023
Operating cash flow -$28.6M-$14.1M
Depreciation and amortisation $2.9M$1.9M
Stock-based compensation $996.0K$754.0K
Capital expenditure $7.4M$4.0M
Investing cash flow -$95.6M$14.0M
Financing cash flow $145.0M$66.0K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001699350-26-000011.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $116.27B 36.1x 11.2%
MMM 3M CO $86.93B 28.1x 1.5%
BSX BOSTON SCIENTIFIC CORP $69.27B 24.6x 19.9%
BDX BECTON DICKINSON & CO $50.32B 31.7x 8.2%
DXCM DEXCOM INC $33.17B 42.1x 15.6%
RMD RESMED INC $32.94B 21.9x 9.9%
MDLN Medline Inc. $31.35B 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $23.93B 50.1x 6.3%